Role of chromogenic in situ hybridization (CISH™) in the evaluation of HER2 status in breast carcinoma:: Comparison with immunohistochemistry and FISH

被引：25
作者：
Li-Ning-T, E [1 ]
Ronchetti, R [1 ]
Torres-Cabala, C [1 ]
Merino, MJ [1 ]
机构：
[1] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA
来源：
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY | 2005年 / 13卷 / 04期
关键词：
chromogenic in situ hybridization (CISH (TM)); fluorescence in situ hybridization (FISH); immunohistochemistry; breast carcinoma; HER2; ERBB2;
D O I：
10.1177/106689690501300406
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
We report Our experience with Chromogenic in Situ Hybridization (CISH (TM)) for the evaluation of HER2 amplification on 55 cases of formalin-fixed, paraffin-embedded invasive breast carcinomas of different histology. All the results were corrected for chromosome 17 aneusomy and compared with immunohistochemistry (IHC); a subset of cases was compared to FISH. Thirty-one of 32 cases in which FISH and CISH (TM) were performed yielded the same results. CISH (TM) and IHC showed a good concordance in the 0/1+ and 3+ category, while a poor agreement with weakly protein overexpression was confirmed. Chromosome 17 analysis was necessary in cases with a low number of HER2 gene copies. CISH (TM) is a useful tool to evaluate breast cancer HER2 status that can be easily implemented in a laboratory of surgical pathology.
引用
收藏
页码：343 / 351
页数：9
相关论文
共 42 条
[1]   THE PRODUCT OF THE HUMAN C-ERBB-2 GENE - A 185-KILODALTON GLYCOPROTEIN WITH TYROSINE KINASE-ACTIVITY [J].
AKIYAMA, T ;
SUDO, C ;
OGAWARA, H ;
TOYOSHIMA, K ;
YAMAMOTO, T .
SCIENCE, 1986, 232 (4758) :1644-1646
[2]   Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer [J].
Arnould, L ;
Denoux, Y ;
MacGrogan, G ;
Penault-Llorca, F ;
Fiche, M ;
Treilleux, I ;
Mathieu, MC ;
Vincent-Salomon, A ;
Vilain, MO ;
Couturier, J .
BRITISH JOURNAL OF CANCER, 2003, 88 (10) :1587-1591
[3]   Evaluating HER2 amplification and overexpression in breast cancer [J].
Bartlett, JMS ;
Going, JJ ;
Mallon, EA ;
Watters, AD ;
Reeves, JR ;
Stanton, P ;
Richmond, J ;
Donald, B ;
Ferrier, R ;
Cooke, TG .
JOURNAL OF PATHOLOGY, 2001, 195 (04) :422-428
[4]   Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation [J].
Chan, KC ;
Knox, WF ;
Gandhi, A ;
Slamon, DJ ;
Potten, CS ;
Bundred, NJ .
BRITISH JOURNAL OF SURGERY, 2001, 88 (03) :412-418
[5]   The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast - A study of a large cohort of patients treated with surgery alone [J].
Cornfield, DB ;
Palazzo, JP ;
Schwartz, GF ;
Goonewardene, SA ;
Kovatich, AJ ;
Chervoneva, I ;
Hyslop, T ;
Schwarting, R .
CANCER, 2004, 100 (11) :2317-2327
[6]   TYROSINE KINASE RECEPTOR WITH EXTENSIVE HOMOLOGY TO EGF RECEPTOR SHARES CHROMOSOMAL LOCATION WITH NEU ONCOGENE [J].
COUSSENS, L ;
YANGFENG, TL ;
LIAO, YC ;
CHEN, E ;
GRAY, A ;
MCGRATH, J ;
SEEBURG, PH ;
LIBERMANN, TA ;
SCHLESSINGER, J ;
FRANCKE, U ;
LEVINSON, A ;
ULLRICH, A .
SCIENCE, 1985, 230 (4730) :1132-1139
[7]   Chromogenic in situ hybridization: A novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma [J].
Dandachi, N ;
Dietze, O ;
Hauser-Kronberger, C .
LABORATORY INVESTIGATION, 2002, 82 (08) :1007-1014
[8]   Subtracted, unique-sequence, in situ hybridization -: Experimental and diagnostic applications [J].
Davison, JM ;
Morgan, TW ;
Hsi, BL ;
Xiao, S ;
Fletcher, JA .
AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (05) :1401-1409
[9]  
Fornier M, 2002, ONCOLOGY-NY, V16, P1340
[10]   Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer [J].
Gupta, D ;
Middleton, LP ;
Whitaker, MJ ;
Abrams, J .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 119 (03) :381-387
12345